<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211612</url>
  </required_header>
  <id_info>
    <org_study_id>LIPOGAIN-2</org_study_id>
    <nct_id>NCT02211612</nct_id>
  </id_info>
  <brief_title>Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation</brief_title>
  <acronym>LIPOGAIN-2</acronym>
  <official_title>Role of Fatty Acids in Skeletal Muscle Hypertrophy and Ectopic Fat Accumulation During Overfeeding (LIPOGAIN-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate metabolic and molecular response to fatty acid-specific overfeeding in
      overweight subjects, in relation to changes in ectopic fat, lean tissue mass and insulin
      sensitivity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lean tissue mass</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by magnetic resonance imaging (MRI) and air displacement plethysmography (BodPod)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic fat content</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue (VAT)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total adipose tissue</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pancreatic fat</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>10 weeks</time_frame>
    <description>Assessed by oral glucose tolerance test (OGTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma lipids</measure>
    <time_frame>10 weeks</time_frame>
    <description>Plasma cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, apolipoprotein B, apolipoprotein A1, free fatty acids, glycerol, proprotein convertase subtilisin/kexin type 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating inflammation and coagulation markers</measure>
    <time_frame>10 weeks</time_frame>
    <description>Plasma tumor necrosis factor-receptor 2, Interleukin receptor 1 antagonist, C-reactive protein, fibrinogen, adhesion molecules</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Circulating hormones and molecular analyses in muscle and fat tissue</measure>
    <time_frame>10 weeks</time_frame>
    <description>Serum hormones including prolactin, tyroxin, T3, cortisol, growth hormone, Insulin growth factor-1. Fat cell morphology assessment in fat tissue, and gene and protein expression, DNA methylation analyses in fat and muscle tissue, palmitate tracer uptake in liver using positron emission tomography</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Obesity</condition>
  <condition>Overfeeding</condition>
  <condition>Muscle Mass</condition>
  <condition>Body Composition</condition>
  <condition>Ectopic Fat</condition>
  <arm_group>
    <arm_group_label>Saturated fatty acids (SFA)-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight gain created by addition of muffins baked on saturated fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyunsaturated fatty acids (PUFA)-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight gain created by addition of muffins baked on polyunsaturated fat</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PUFA-group</intervention_name>
    <arm_group_label>Polyunsaturated fatty acids (PUFA)-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SFA-group</intervention_name>
    <arm_group_label>Saturated fatty acids (SFA)-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index 25-32

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Type 1 diabetes

          -  Kidney disease

          -  Liver disease

          -  Abnormal clinical chemistry at screening

          -  Intense physical exercise &gt; 2 hours per week

          -  Use of statins or drugs affecting energy metabolism

          -  Use of extreme diets
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Riserus</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University; Clinical nutrition and metabolism; Dept of public health and caring sciences</name>
      <address>
        <city>Uppsala</city>
        <state>Please Select</state>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>David Iggman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Overfeeding</keyword>
  <keyword>Weight gain</keyword>
  <keyword>Liver fat</keyword>
  <keyword>Pancreatic fat</keyword>
  <keyword>Ectopic fat</keyword>
  <keyword>Skeletal muscle</keyword>
  <keyword>Adipose tissue</keyword>
  <keyword>Gene expression</keyword>
  <keyword>DNA methylation</keyword>
  <keyword>Palmitate</keyword>
  <keyword>Linoleic acid</keyword>
  <keyword>Saturated fat</keyword>
  <keyword>Polyunsaturated fat</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

